Results 51 to 60 of about 27,357 (215)

Successful treatment of pulmonary mucormycosis caused by Rhizopus microsporus with posaconazole

European Journal of Medical Research, 2021
Background Mucormycosis is a rare fungal infection occurring chiefly in the lung or the rhino-orbital-cerebral compartment, particularly in patients with immunodeficiency or diabetes mellitus. Among Mucorales fungi, Rhizopus spp.
F. Yuan, Jun Chen, F. Liu, Y. Dang, QingTao Kong, H. Sang   +5 more
semanticscholar   +1 more source

Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. [PDF]

, 2017
F901318 is an antifungal agent with a novel mechanism of action and potent activity against Aspergillus spp. An understanding of the pharmacodynamics (PD) of F901318 is required for selection of effective regimens for study in phase II and III clinical ...
Adam Johnson, Anthony Kennedy, Derek Law, Joanne Livermore, John H. Rex, Julie Schwartz, Laura McEntee, Michael Birch, Nicola Farrington, Robert A. Bonomo, Ruwanthi Kolamunnage-Dona, Sarah Whalley, William W. Hope   +12 more
core   +2 more sources

Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review

Clinical Infectious Diseases
Background Primary antifungal prophylaxis with mold-active azoles is used to prevent invasive fungal infections in patients with high-risk hematological disorders; however, breakthrough infections occur, and the reasons for treatment failure are still ...
Catherine-Audrey Boutin, Florence Durocher, Stéphanie Beauchemin, Daniela Ziegler, C. A. Abou Chakra, S. Dufresne   +5 more
semanticscholar   +1 more source

Characterization of Therapeutic Drug Monitoring Practices of Voriconazole and Posaconazole at a Pediatric Hospital.

The Journal of Pediatric Pharmacology and Therapeutics, 2021
OBJECTIVES To characterize the voriconazole and posaconazole serum trough ordering practices in patients receiving prophylactic and treatment antifungal therapy.
S. Duehlmeyer, Christopher Klockau, Diana Yu, J. Rouch   +3 more
semanticscholar   +1 more source

The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2020
Posaconazole is a broad-spectrum triazole antifungal agent with potent activity against various fungi, including yeast and molds, including Mucorales, what makes a key difference with itraconazole and voriconazole.
Veselov A.V.
doaj   +1 more source

Multicenter, International Study of MIC/ MEC Distributions for definition of epidemiological cutoff values for sporothrix species identified by molecular methods [PDF]

, 2017
Clinical and Laboratory Standards Institute (CLSI) conditions for testing the susceptibilities of pathogenic Sporothrix species to antifungal agents are based on a collaborative study that evaluated five clinically relevant isolates of Sporothrix ...
Abreu, D.P.B., Almeida-Paes, R., Ballesté Alaniz, R., Bonfietti, L.X., Bonifaz, A., Brilhante, R.S.N., Chakrabarti, A., Chowdhary, A., Córdoba, S., Espinel-Ingroff, A., et al., Gonzalez, G.M., Govender, N.P., Guarro, J., Hagen, F., Johnson, E.M., Kidd, S., Pereira, S.A., Rodrigues, A.M., Rozental, S., Szeszs, M.W.   +20 more
core   +1 more source

Comparative clinical and economic analysis of pozaconazol (Noxafil) for invasive mycoses (IM) prevention in patients with severe neutropenia during treatment of acute myeloid leukemia or myelodysplastic syndrome

Онкогематология, 2019
Objective: a comparative clinical and economic analysis of posaconazole (Noxafil) for invasive mycoses (IM) prevention in patients with severe neutropenia during treatment of acute myeloid leukemia or myelodysplastic syndrome in Russia.
I. S. Krysanov, N. N. Klimko, V. Yu. Ermakova, V. S. Krysanova   +3 more
doaj   +1 more source

The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf

Medical Mycology Case Reports, 2021
Mucorales infections in cetaceans have a high mortality rate. This case report refers to a bottlenose dolphin calf with suspected mucormycosis treated with posaconazole.
Gonçalo N. Marques, Nuno U. Silva, Miriam O. Leal, Carla A. Flanagan   +3 more
doaj   +1 more source

A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication

Therapeutic Drug Monitoring, 2021
Background: Posaconazole oral suspension emerged as a promising candidate for prophylaxis of invasive fungal infections in immunocompromised children.
Omar Elkayal, I. Spriet, A. Uyttebroeck, A. Colita, P. Annaert, K. Allegaert, A. Smits, R. Van Daele, E. Dreesen   +8 more
semanticscholar   +1 more source

Posaconazole

Drugs in R & D, 2003
Posaconazole [SCH 56592, SPRIAFIL, Noxafil] is an orally active triazole derivative that is in phase III trials with the Schering-Plough Research Institute (SPRI) in the US for the treatment of serious opportunistic fungal infections, including aspergillosis, candidiasis, coccidioidomycosis and fusariosis.
openaire   +2 more sources